SCHEMBL26565169

SCHEMBL26565169

CCc1cccc(C(O)c2ccc3nc(OC)cc(-c4cccc(O[Si](C(C)C)(C(C)C)C(C)C)c4)c3c2)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 2/20 0.35
PTGS2 P35354 2/20 0.33
AKR1C3 P42330 3/20 0.32
AKR1C2 P52895 3/20 0.32
CASR P41180 1/20 0.32
MAPT P10636 2/20 0.32
ATM Q13315 1/20 0.32
USP2 O75604 2/20 0.32
ALDH1A1 P00352 2/20 0.32
LMNA P02545 2/20 0.32
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C9 P11712 2/20 0.32
TSHR P16473 2/20 0.32
MAPK1 P28482 2/20 0.32
CYP2C19 P33261 2/20 0.32
HSD17B10 Q99714 2/20 0.32
CLK4 Q9HAZ1 2/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26565302 0.93 PKM (0.35) LTB4RAKR1C3AKR1C2CASRMAPT
SCHEMBL26565190 0.87 LTB4R (0.36) LTB4RPTGS2AKR1C3AKR1C2GPR84
SCHEMBL26565276 0.84 LTB4R (0.36) LTB4RPTGS2AKR1C3AKR1C2DGAT2
SCHEMBL26565316 0.84 LTB4R (0.33) LTB4RPTGS2AKR1C3AKR1C2DGAT2
SCHEMBL26565167 0.83 LTB4R (0.39) LTB4RAKR1C3AKR1C2MAPTATM
SCHEMBL26564919 0.80 SOS1 (0.33) LTB4RCASRALDH1A1CYP2D6CYP2C19
SCHEMBL25224251 0.78 L3MBTL1 (0.43) LTB4RMAPTATMUSP2ALDH1A1
SCHEMBL30533422 0.78 L3MBTL1 (0.43) LTB4RMAPTATMUSP2ALDH1A1
SCHEMBL30533423 0.78 L3MBTL1 (0.43) LTB4RMAPTATMUSP2ALDH1A1
SCHEMBL26565300 0.77 LTB4R (0.38) LTB4RAKR1C3AKR1C2AVPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018011-B2 Macrocyclic compounds and compositions, and methods of preparing and using the same KURA ONCOLOGY, INC. (US) 2024-06-25 US disclosed
US-20230322711-A1 MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME WUXI APPTEC (HONG KONG) LIMITED (CN) 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018011-B2 Macrocyclic compounds and compositions, and methods of preparing and using the same FNTA, FDPS, GGPS1 LTB4R 2287/4885PTGS2 2724/4885AKR1C3 391/4885
US-20230322711-A1 MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME FNTA, FDPS, GGPS1 LTB4R 2287/4885PTGS2 2724/4885AKR1C3 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.